Prevencio
Prevencio is a biotechnology company specializing in AI-powered, multi-protein blood tests for cardiovascular disease (CVD) detection and risk prediction. Their patented HART tests provide earlier, more accurate, and less invasive diagnosis of coronary artery disease, heart attack, stroke, and other cardiovascular events, improving patient outcomes and reducing unnecessary procedures. The company collaborates with leading medical institutions and has received FDA breakthrough device designation and CPT PLA reimbursement codes, validating the commercial and clinical value of their tests. Prevencio's business model includes selling these diagnostic tests primarily to healthcare providers and patients, with ongoing development of new tests and partnerships to expand market reach.
Prevencio
Prevencio is a biotechnology company specializing in AI-powered, multi-protein blood tests for cardiovascular disease (CVD) detection and risk prediction. Their patented HART tests provide earlier, more accurate, and less invasive diagnosis of coronary artery disease, heart attack, stroke, and other cardiovascular events, improving patient outcomes and reducing unnecessary procedures. The company collaborates with leading medical institutions and has received FDA breakthrough device designation and CPT PLA reimbursement codes, validating the commercial and clinical value of their tests. Prevencio's business model includes selling these diagnostic tests primarily to healthcare providers and patients, with ongoing development of new tests and partnerships to expand market reach.
TL;DR
What they do: AI-driven, multi‑protein blood tests (HART) for detection and risk stratification of cardiovascular disease
Headquarters: Kirkland, Washington
Founded: 2013
Recent funding signal: Non-equity assistance round led by MedTech Innovator (May 2024)
Team size (reported): Approximately 11 employees
Company Overview
Problem Domain
Cardiovascular disease detection, diagnosis, and risk stratification
Founded
2013
Industry
Biotechnology
Tech Stack
Funding Track Record
May 2024 non‑equity assistance round led by MedTech Innovator reported in public profiles
Investor Signal
“MedTech Innovator noted as lead/funder in May 2024 non‑equity assistance round”